The major objective of this course is to provide a detailed insight into the practical aspects and approaches of process scale-up for different unit operations and technologies.
Meet your quality and compliance goals with Fleming.
COMPLYING with quality requirements is a must for a scientifically & ethically valid clinical trial. Globalization, outsourcing and the increasing complexity of clinical trials has resulted in a novel compliance scenario regarding international quality standards for clinical trials.
To make it easier for you to meet regulatory expectations and quality standards for every clinical trial, Fleming. has decided to organize the Clinical Quality & Compliance Masterclass.
Experts from Pfizer, Roche, Sanofi, Boehringer Ingelheim, AstraZeneca, Bayer and others will gather on 16 – 17 June 2016 in Vienna, Austria to discuss how to manage clinical quality for greater compliance, effectiveness & audit readiness.
During the two interactive days, attendees will have the opportunity to gain practical tips from a GCP inspector during an on-stage interview, get deeper insight into key drivers of clinical quality under the recent GCP guideline amendments, explore new approaches to auditing investigator sites with a risk-based monitoring model, ensure the sponsor accountabilities in the quality oversight in an outsourced model, and much more.
Participants will have the opportunity to work on practical tasks and share their results on winning tactics & strategies for achieving the highest quality, cost efficiency and operational excellence during three built-in workshops.
Interested in this topic?
Targeted Drug Delivery
Gain detailed overview of the newest strategies in drug delivery and targeting.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?